The Drugs Controller General of India (DCGI) has approved the adult population's access to the anti-Covid-19 vaccinations Covishield and Covaxin. This information came from an official source. According to sources, the vaccination will not be sold in medical stores. Hospitals and clinics can purchase vaccines, but they must furnish DCGI with vaccination data every six months.
Sources indicated a day earlier on Wednesday that the cost of both vaccines would likely be regulated at Rs 275 per dosage plus a Rs 150 service charge. The National Pharmaceutical Pricing Authority (NPPA) has been asked to begin working on setting price caps for vaccines to make them more affordable.
Covaccine costs Rs 1,200 per dosage so far, while a single dose of Covishield costs Rs 780 in private institutions. A service charge of Rs.150 is also included in the prices. Both vaccinations are currently only approved for emergency usage in the country.
The Central Drugs Standard Control Organization's (CDSCO) Subject Expert Committee on Covid-19 recently approved the normal launch of the anti-Covid vaccinations Covishield and Covaccine for use among the adult population, subject to specific criteria. was suggested.
On October 25, Prakash Kumar Singh, Director (Government and Regulatory Affairs), Serum Institute of India, applied to the Drug Controller General of India for permission to commercialize the Covishield vaccine. V Krishna Mohan, Bharat Biotech's full-time director, filed detailed information on chemistry, manufacturing, and control, as well as clinical data, requesting regular approval for the vaccine a few weeks ago. On January 3 of last year, Covaccine and Covishield received Emergency Use Approval (EUA).